Scottish Medicines Consortium Accepts ABRAXANE® for Use within National Health Service for Scotland

LOS ANGELES--(BUSINESS WIRE)-- Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, welcomes the announcement today that following a full submission, the Scottish Medicines Consortium (SMC) has accepted ABRAXANE® (paclitaxel albumin) for restricted use within the National Health Service (NHS) for Scotland in patients who would otherwise receive docetaxel or 3-weekly solvent-based paclitaxel as second-line treatment for metastatic breast cancer.

“ABRAXANE’s acceptance by the SMC is a significant milestone in our goal to provide patients in the United Kingdom and across Europe with an innovative treatment option,” said Jean-François Gimonet, M.D., Vice President, European Operations of Abraxis BioScience.

For further information on the SMC’s decision, please visit their website at

About Abraxis BioScience, Inc.

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s product pipeline is based on a proprietary tumor targeting technology known as the nab® (nanoparticle albumin bound) platform. The company continues to expand the nab® platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit


Investors and Media Inquiries
Abraxis BioScience, Inc.
Maili Bergman, +1 310-883-1300
[email protected]
Media Inquiries
Zeno Group
Victoria Fort, +1 202-361-0445
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical